Roche’s Enspryng (satralizumab), a thyroid eye disease (TED) treatment, has been accepted by the FDA and given priority ...

For pharma, its AI progress appears to be slowed by a methodical procession of AI adoption through a series of chicanes.

Oxford BioTherapeutics (OBT) has announced two clinical milestones from its long-running oncology collaboration with ...

A single word—manageable—can minimise the real burden of treatment side effects, and it’s time clinical trial communication ...

Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective 6 July 2026. Sims is a seasoned oncology ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies ...

MRM Health has appointed Hans-Jürgen Wörle to join the Board as an Independent Director. Wörle brings substantial M&A and ...

Mental health has been at the centre of our business since our inception. But that work doesn't just extend to our client ...

Takeda has presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin ...

Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal valued at up to $7bn, as the company looks to expand its capabilities in cell and gene therapy. Under the terms of the agreement, Kelonia ...

Sanofi has appointed Paulo Fontoura as Executive Vice President, Global Head of Research & Development Pharma, effective 1 ...